At the cutting edge of biotechnology
iX Biopharma focuses on the development and commercialisation of novel wafer formulations to improve the quality of life of those suffering from pain and other health conditions
Add BT as a preferred source
SINCE joining Singapore Exchange (SGX)-listed specialty pharmaceutical company iX Biopharma, Janakan Krishnarajah has been getting involved in many new aspects of the drug making business.
Dr Krishnarajah, a specialist in the fields of clinical pharmacology and internal medicine, had previously held the position of CEO and medical director at Linear Clinical Research - an Australian clinical trials facility.
There, the 42-year-old developed extensive experience in Phases I-IV clinical trials. He acted as principal or co-investigator in more than a hundred Phase I-II clinical trials.
TRENDING NOW
Lian Beng Group’s Ong family members pick up two bungalows in Belmont Road for S$60 million
Vingroup’s shares surge 1,000% to overtake regional heavyweights including Singtel and JD.com
URA lifts ban on new hotels, hostels and serviced apartments in Boat Quay, Beach Road areas
Singtel gets funding boost from government to strengthen AI push, create high-value roles
